Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer
PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Listed as NCT00002903, this PHASE2 trial focuses on Extragonadal Germ Cell Tumor and Ovarian Cancer and remains completed. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 6 times since 1995, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 1995
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Aviano, Italy , Basel, Switzerland , Bellinzona, Switzerland , Bern, Switzerland , Bordeaux, France , Brussels, Belgium , Clermont-Ferrand, France , Copenhagen, Denmark , Dijon, France and 36 more locations